Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 7 Novo Nordisk aims for leadership in long-acting insulin and sustained leadership for fast-acting and premix insulin Long-acting insulin¹ volume market share across regions Novo Nordisk Region China Fast-acting insulin² volume market share across regions North America Operations Region Japan & Korea Premix insulin³ volume market share across regions Region Europe Region AAMEO 80% 70% 60% 50% 40% 30% 20% 10% 0% Feb 2013 80% 70% 60% 50% 40% 30% 20% 10% 0% Feb 2018 Feb 2013 Region Latin America 80% 70% 60% 50% 40% 30% 20% 10% 0% Feb Feb 2018 2013 Feb 2018 1 Long-acting insulin comprises: TresibaⓇ, Levemir®, XultophyⓇ and Insulatard® (basal human insulin). Please note that not all products are launched in all markets 2 Short-acting insulin includes: Fiasp®, NovoLog® and Mixtard® 30 (premix human insulin). Please note that not all products are launched in all markets 3 Premix insulin includes: RyzodegⓇ, NovoMix® and ActrapidⓇ (bolus human insulin). Please note that not all products are launched in all markets changing diabetes® novo nordisk

View entire presentation